CPT 81539 PSA/hK2 Risk Score Reimbursement | OpenPayer

Summary & Overview

CPT 81539: Multianalyte PSA and hK2 Algorithmic Risk Score

CPT code 81539 represents a laboratory multianalyte algorithmic test that measures total PSA, free PSA, intact PSA, and human kallikrein–2 (hK2) and reports a predictive probability score for high–grade prostate cancer. This advanced diagnostic assay is clinically important for refining risk assessment in men with elevated PSA or other indications for prostate cancer evaluation, potentially influencing further diagnostic steps such as imaging or biopsy.

Key national payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage landscapes, common billing modifiers, and clinical context for test utilization. The publication outlines typical sites of service and the laboratory nature of the procedure, and it presents benchmarking and policy considerations relevant to multianalyte algorithmic tests.

This summary provides clinicians, billing professionals, and policy analysts with the clinical purpose of the code, payer scope, and what to expect from documentation and coding perspectives. Data not available in the input for specific reimbursement rates, associated taxonomies, ICD-10 pairings, and related codes are noted as unavailable in detailed sections of the full publication.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare81539CPTmultianalyte testprostate cancerPSAkallikreinlaboratory diagnosticsrisk score

Billing Code Overview

CPT code 81539 describes a laboratory-based multianalyte algorithmic test that measures total prostate specific antigen (PSA), free PSA, intact PSA, and human kallikrein–2 (hK2) in blood and applies a predictive algorithm to report a probability score for high–grade prostate cancer. The service combines analytical laboratory procedures with an interpretive, algorithm-driven risk score.

Service type: Laboratory multianalyte test with algorithmic interpretation
Typical site of service: Clinical laboratory or reference laboratory performing blood-based diagnostic testing

Clinical & Coding Specifications

Clinical Context

A typical patient is a man aged 50–75 referred by a urologist or primary care clinician for risk assessment of prostate cancer after an elevated total prostate specific antigen (PSA), abnormal digital rectal exam, or prior negative biopsy with ongoing concern. A blood specimen is collected in an outpatient clinic, ambulatory surgery center, or hospital outpatient lab. The specimen is sent to a clinical laboratory where a laboratory technologist performs immunoassays for total PSA, free PSA, intact PSA, and human kallikrein-2 (hK2). Technical processing includes specimen accessioning, aliquoting, running validated assays, quality controls, and generating quantitative results. A laboratory information system applies the validated predictive algorithm to compute a probability score for high-grade (Gleason ≥7) prostate cancer. The final report transmitted to the ordering clinician includes the assay values, the algorithm-derived probability score, assay limitations, and interpretive comments. Typical sites of service: outpatient physician office collection, independent clinical laboratory, hospital outpatient laboratory, and reference laboratory. Common clinical workflow steps: clinician orders the test, phlebotomy collection, specimen transport to the testing laboratory, technical assay performance and algorithm computation, result verification, and result reporting to the ordering clinician for integration into clinical decision-making about biopsy or surveillance.

Coding Specifications

Modifier	Description	When to Use

CPT 81525: Colon Tumor 12-Gene RT–PCR Recurrence Score

CPT-81541-PROSTATE-CANCER-46-GENE-EXPRESSION-RISK-SCORE

CPT 81541: Prostate Cancer 46‑Gene mRNA Expression Risk Score

CPT-81528-STOOL-DNA-AND-FECAL-HEMOGLOBIN-COLORECTAL-CANCER-SCREENING

CPT 81528: Stool DNA and Fecal Hemoglobin Colorectal Cancer Screening Test

CPT-81521-BREAST-CANCER-RECURRENCE-SCORE-MOLECULAR-DIAGNOSTICS

CPT 81521: mRNA Microarray Breast Cancer Recurrence Score

CPT-81524-CNS-TUMOR-DNA-METHYLATION-PROFILING-MGMT

CPT 81524: CNS Tumor DNA Methylation Profiling

CPT-81511-MULTIANALYTE-SERUM-SCREENING-ALGORITHMIC-RISK-SCORE

CPT 81511: Multianalyte Serum Screening with Algorithmic Risk Score

CPT-81513-MOLECULAR-BV-ASSAY-VAGINAL-FLUID-ALGORITHMIC-REPORT

CPT 81513: Molecular BV Assay on Vaginal Fluid with Algorithmic Interpretation

CPT-81554-MRNA-PANEL-USUAL-INTERSTITIAL-PNEUMONIA-UIP

CPT 81554: mRNA Gene Expression Profiling for Usual Interstitial Pneumonia

CPT-81519-21-GENE-BREAST-CANCER-RECURRENCE-SCORE

CPT 81519: 21-Gene Breast Cancer Recurrence Score Test

CPT-81503-ALGORITHMIC-LAB-RISK-SCORE-CA125-APOLIPOPROTEIN-A1

CPT 81503: Algorithmic Laboratory Risk Score Using Multiple Biomarkers

Showing 1–10 of 41

Taxonomy Code	Specialty	Notes
208000000X	Pathology	Clinical pathologists or laboratory medicine specialists overseeing testing and interpretation
207K00000X	Urology	Ordering clinicians who manage prostate disease and interpret results for biopsy decisions
207Q00000X	Family Medicine	Primary care clinicians ordering initial PSA-based risk assessment
207R00000X	Internal Medicine	Internists ordering or following prostate cancer risk assessments
364SF0200X	Phlebotomy	Clinical laboratory personnel and phlebotomists performing specimen collection and handling

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R97.2`	Elevated prostate specific antigen [PSA]	Primary indication for ordering comprehensive PSA isoform and kallikrein testing to refine cancer risk
`N40`	Benign prostatic hyperplasia	Common cause of elevated PSA; differentiation from malignancy may prompt use of multi-marker risk testing
`N44.89`	Other disorders of the male genital organs	Used when non-specific male genital findings prompt further PSA-based evaluation
`N41.9`	Inflammatory disease of prostate, unspecified	Prostatitis can elevate PSA; testing may be used in differential assessment before biopsy
`Z12.5`	Encounter for screening for malignant neoplasm of prostate	Use when ordered as part of prostate cancer screening in appropriate clinical contexts

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80053`	Comprehensive metabolic panel	Common baseline laboratory panel ordered concurrently for preprocedural evaluation or general health assessment
`85025`	Complete blood count (CBC) with automated differential	Often ordered alongside to assess hematologic status prior to invasive procedures like prostate biopsy
`81002`	Urinalysis, non-microscopic, with reagent strip	May be ordered to evaluate urinary infection or hematuria before prostate biopsy
`82105`	Assay of prostate specific antigen (PSA) — total	Standard single-analyte PSA test; `81539` extends to a multi-marker panel with algorithmic risk prediction
`88342`	Immunohistochemistry, per specimen; initial single antibody stain	Performed on biopsy tissue when prostate biopsy is obtained following elevated risk score
`88305`	Level IV surgical pathology, gross and microscopic examination	Performed on prostate biopsy cores after biopsy is performed following risk assessment

`00`	Unmodified claim	Standard use when no modifier applies
`11`	—	Data not available in the input
`22`	Increased procedural services	Use when work or resources substantially exceed typical laboratory processing for the assay (rare)
`26`	Professional component	Use when billing only the physician or pathologist professional interpretation component (if applicable)
`52`	Reduced services	Use when testing was partially reduced or limited
`53`	Discontinued procedure	Use when test processing was started but discontinued for documented clinical reasons
`59`	—	Data not available in the input
`62`	Two surgeons	— Not typically applicable to lab-based testing; included when applicable in complex service arrangements
`90`	Reference (outside) laboratory	Use when the performing laboratory is an outside/reference lab billed differently than the ordering lab
`TC`	Technical component	Use when billing only the laboratory technical component of the service
`QK`	Medical direction of two or more qualified health care professionals	— Not typically used for lab testing but present in modifier list
`QX`	Order of service by non-physician practitioner	Use when a qualified non-physician clinician orders the test under applicable coverage rules
`QY`	Attending practitioner of record	Use where applicable under Medicare rules for lab services
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services	Use when these practitioners perform or order the service per payer policy

OpenPayer